5315992025-04-012025-06-305315992025-04-012025-06-30in-capmkt:OtherExpenses1Member5315992025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15315992025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares531599FDCNOTLISTEDINE258B01022FDC LimitedMain BoardEquity2025-04-012026-03-312025-08-072025-08-01INRLakhsQuarterlyFirst quarterSingle segmentpharmaceutical2025-08-0712:30:002025-08-0713:55:00Not applicable2025-04-012025-06-30UnauditedConsolidated648405800035504200068391000001783075000342838000-3357300013237340001166300014906800016645420005241347000159775300001597753000350322000339170003842390000121351400000001213514000-60760001207438000121351400001207438000016281000017.457.45007.457.451. The above unaudited consolidated financial results which are published in accordance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company at their meeting held on August 7, 2025. The Statutory Auditors have carried out a limited review of the above results and have expressed an unmodified review conclusion. <BR> 2. The Parent Company recognized a fair value loss of Rs. 197.01 lakhs under other expenses in the quarter ended March 31, 2025 in accordance with Ind AS 109 (Financial Instruments). However, for the financial year ended March 31, 2025, a net fair value gain of Rs. 2,430.09 lakhs was recorded under Other Income. Due to this treatment, the quarterly numbers may not be directly additive to the year-to-date (YTD) numbers, as fair value changes are recognized based on market conditions prevailing at different reporting dates. <BR> 3. During the previous financial year, the Parent Company has paid an Interim Dividend of Rs.5/- per equity share of face value Rs.1/- each for the Financial Year 2024-25, as approved by the Board of Directors of the Parent Company at their meeting held on November 6, 2024. <BR> 4. Figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year ended as on March 31, 2025 and the published year-to-date figures up to end of the third quarter ended as on December 31, 2024 of the relevant financial year. Also, the figures upto the end of third quarter had only been reviewed and not subjected to audit. <BR> 5. The Group has only one segment of activity namely “Pharmaceuticals”. <BR> 6. The above results are also available on the website of the Parent Company i.e. www.fdcindia.com and on the website of the Stock Exchanges i.e. www.nseindia.com and www.bseindia.com. <BR> Other Expenses1664542000Items that will not be reclassified subsequently to profit or loss-11049000-11049000-2618000Items that will be reclassified subsequently to profit or loss235500023550000-6076000